Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of subcutaneous CM313 in primary IgA nephropathy
CTR20250478Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cm313 in IgA nephropathy (IgAN), sponsored by Keymed Biosciences. Started Dec 2025; status: active.
02
Drugs
cm313
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20250478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250478.